{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
NCT04304482: Phase 2/Phase 3 Interventional Completed Rett Syndrome
(2020)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
AE-37 (ANAVEX2-73, Tetrahydro-N, N-dimethyl-2, 2-diphenyl-3-furanemethanamine) is an orally available drug candidate developed to potentially modify Alzheimer’s disease rather than temporarily address its symptoms. It has a clean Phase 1 data profile and shows a reversal of memory loss (anti-amnesic properties) and neuroprotection in several models of Alzheimer’s disease. This drug is in Phase II trials for Alzheimer's disease, phase I trials for epilepsy, and in preclinical trials for amyotrophic lateral sclerosis, Parkinson's disease, Rett syndrome, stroke. AE-37 may function as a pro-drug for ANAVEX19-144 and acts as a muscarinic receptor and a moderate sigma1 receptor agonist.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ACHIRAL)
Oxeglitazar (also known as EMD 336340 or LM 4156), an orally administered poorly water-soluble dual peroxisome proliferator-activated receptor α/γ agonist. This drug was used in the treatment of type II diabetes mellitus and metabolic syndrome. In addition, oxeglitazar participated in phase I trials for the gout treatment; however, this study was halted. Information about the further development of this drug is not available.
Status:
Investigational
Source:
INN:gridegalutamide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Sodium nivimedone (BRL10833) is an orally administered anti-allergic agent with similar properties to DSCG. Nivimedone inhibited IgE-mediated passive cutaneous anaphylactic (PCA) reactions in the rat and the antigen-induced release of histamine from human lung passively sensitized with atopic serum. The pharmacological potency of sodium nivimedone when compared to DSCG was 42 times greater in the human lung system and approximately ten times greater in rat PCA. In addition, single doses of sodium nivimedone given by mouth inhibited antigen-induced bronchoconstriction in man.
Status:
Investigational
Source:
NCT03993704: Phase 1 Interventional Completed Healthy
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:sonzivotide filricianine [INN]
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Investigational
Source:
NCT04220411: Phase 1/Phase 2 Interventional Terminated Dermatitis, Atopic
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
INN:bemnifosbuvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
